or Try an Advanced Search...

    Technical Analysis for ENTO - Entero Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 1.85 -10.55% -0.22
    ENTO closed up 6.7 percent on Thursday, June 20, 2024, on 2.94 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Jun 21
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ENTO trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup -10.55%
    Lower Bollinger Band Walk Weakness -10.55%
    New 52 Week Low Weakness -10.55%
    Outside Day Range Expansion -10.55%
    Wide Bands Range Expansion -10.55%
    Lower Bollinger Band Touch Weakness -10.55%
    Oversold Stochastic Weakness -10.55%
    New 52 Week Closing Low Bearish -4.55%
    Lower Bollinger Band Walk Weakness -4.55%
    Inside Day Range Contraction -4.55%
    Older End-of-Day Signals for ENTO ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 2 hours ago
    Lower Bollinger Band Support about 3 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    Down 5% about 3 hours ago
    Fell Below Lower Bollinger Band about 3 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ENTO Chart by TradingView
    Basic chart:

    Profile

    Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19

    Is ENTO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 22 Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
    May 20 Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
    May 16 First Wave BioPharma changes name to Entero Therapeutics
    May 16 First Wave BioPharma Changes Name to Entero Therapeutics
    May 10 First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
    May 9 First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
    Apr 29 Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
    Apr 24 First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
    Apr 17 First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
    Apr 15 First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
    See more ENTO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 34.8
    52 Week Low 1.81
    Average Volume 36,354
    200-Day Moving Average 4.91
    50-Day Moving Average 2.73
    20-Day Moving Average 2.43
    10-Day Moving Average 2.20
    Average True Range 0.28
    RSI (14) 34.21
    ADX 37.11
    +DI 8.89
    -DI 21.00
    Chandelier Exit (Long, 3 ATRs) 2.17
    Chandelier Exit (Short, 3 ATRs) 2.64
    Upper Bollinger Bands 3.00
    Lower Bollinger Band 1.87
    Percent B (%b) 0.18
    BandWidth 46.63
    MACD Line -0.24
    MACD Signal Line -0.22
    MACD Histogram -0.025
    Fundamentals Value
    Market Cap 3.23 Million
    Num Shares 1.56 Million
    EPS 1131.40
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 2.56
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.79
    Resistance 3 (R3) 2.78 2.54 2.67
    Resistance 2 (R2) 2.54 2.35 2.54 2.63
    Resistance 1 (R1) 2.30 2.24 2.42 2.31 2.59
    Pivot Point 2.06 2.06 2.12 2.06 2.06
    Support 1 (S1) 1.82 1.87 1.94 1.83 1.55
    Support 2 (S2) 1.58 1.76 1.58 1.51
    Support 3 (S3) 1.34 1.58 1.47
    Support 4 (S4) 1.35